📣 Help Shape the Future of UKRI's Gateway to Research (GtR)

We're improving UKRI's Gateway to Research and are seeking your input! If you would be interested in being interviewed about the improvements we're making and to have your say about how we can make GtR more user-friendly, impactful, and effective for the Research and Innovation community, please email gateway@ukri.org.

Antibody decay, T cell immunity and breakthrough infections following two SARS-CoV-2 vaccine doses in inflammatory bowel disease patients treated with infliximab and vedolizumab. (2022)

First Author: Lin S

Attributed to: Phase 1 COVID-19 Data and Connectivity – National Core Study (Phase 1 D&C-NCS) funded by COVID

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.1038/s41467-022-28517-z

PubMed Identifier: 35296643

Publication URI: http://europepmc.org/abstract/MED/35296643

Type: Journal Article/Review

Volume: 13

Parent Publication: Nature communications

Issue: 1

ISSN: 2041-1723